Recursion Pharmaceuticals, Inc.
MX ˙ BMV ˙ US75629V1044
SecurityMX:RXRX / Recursion Pharmaceuticals, Inc.
InstitutionMarshall Wace, Llp
Latest Disclosed Ownership2,876,928 shares
Latest Disclosed Value $ 8,832,169
Marshall Wace, Llp reports 1,169.56% increase in ownership of RXRX / Recursion Pharmaceuticals, Inc.

On May 14, 2026 - Marshall Wace, Llp filed a 13F-HR form disclosing ownership of 2,876,928 shares of Recursion Pharmaceuticals, Inc. (MX:RXRX) valued at $8,832,169 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 226,609 shares of Recursion Pharmaceuticals, Inc.. This represents a change in shares of 1,169.56% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F RECURSION PHAR-A COMMON STOCK 75629V104 2,876,928 2,650,319 1,169.56 8,832 853.78 0.0042
2026-02-13 2025-12-31 13F RECURSION PHAR-A COMMON STOCK 75629V104 226,609 148,350 189.56 927 143.04 0.0008
2025-11-13 2025-09-30 13F RECURSION PHAR-A COMMON STOCK 75629V104 78,259 -8,053 -9.33 382 -12.61 0.0004
2025-08-13 2025-06-30 13F RECURSION PHAR-A COMMON STOCK 75629V104 86,312 -247,300 -74.13 437 -75.28 0.0005
2025-05-15 2025-03-31 13F RECURSION PHAR-A COMMON STOCK 75629V104 333,612 333,612 1,765 0.0022
2024-08-14 2024-06-30 13F RECURSION PHAR-A COMMON STOCK 75629V104 0 -391,518 -100.00 0 -100.00
2024-05-15 2024-03-31 13F RECURSION PHAR-A COMMON STOCK 75629V104 391,518 391,518 3,903 0.0059
2023-08-14 2023-06-30 13F RECURSION PHAR-A COMMON STOCK 75629V104 0 -514,137 -100.00 0 -100.00
2023-05-15 2023-03-31 13F RECURSION PHAR-A COMMON STOCK 75629V104 514,137 514,137 3,429 0.0073
2022-11-14 2022-09-30 13F RECURSION PHAR-A COMMON STOCK 75629V104 0 -106,786 -100.00 0 -100.00
2022-08-15 2022-06-30 13F RECURSION PHAR-A COMMON STOCK 75629V104 106,786 106,786 869 0.0018
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.